Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.

@article{Gudjonsson2009ShouldAP,
  title={Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.},
  author={Sigurdur V Gudjonsson and Lars Adell and Fekadu Merdasa and Ronnie Olsson and Bruno Larsson and Thomas Davidsson and Jonas Richthoff and Gunnar Hagberg and Magnus Grabe and P{\"a}r Ola Bendahl and Wiking M{\aa}nsson and Fredrik Liedberg},
  journal={European urology},
  year={2009},
  volume={55 4},
  pages={773-80}
}
BACKGROUND To decrease recurrences in non-muscle-invasive bladder cancer (NMIBC), the European Association of Urology (EAU) guidelines recommend immediate, intravesical chemotherapy after transurethral resection (TUR) for all patients with Ta/T1 tumours. OBJECTIVE To study the benefits of a single, early, intravesical instillation of epirubicin after TUR in patients with low- to intermediate-risk NMIBC. DESIGN, SETTING, AND PARTICIPANTS In this prospective randomised multicentre trial, 305… CONTINUE READING
66 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…